Evotec SE announced that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc. The collaboration focuses on the development of first-in-class targeted immune-based therapies for oncology, which will ultimately be commercialised by Janssen. The agreement was facilitated by Johnson & Johnson Innovation. The collaboration leverages Evotec's integrated discovery and development capabilities and manufacturing optimisation processes, including an option for the GMP manufacture of the immune-based therapies.

Evotec will collaborate closely with Janssen during the pre-clinical R&D phase while Janssen will assume full responsibility for the clinical development and commercialisation. Besides research funding, Evotec is entitled to an undisclosed upfront payment, success-based research and commercial milestones exceeding USD 350 million as well as tiered royalties on products resulting from the collaboration.